PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.
The recent development of a novel class of insulin-sensitizing drugs, the thiazolidinediones (TZDs), represents a significant advance in antidiabetic therapy. One key mechanism by which these drugs exert their effects is by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma), a member of the nuclear receptor family. Evidence supporting this mechanism of action of the TZDs will be reviewed in this article. Recent data suggests that PPAR-gamma agonists might also have therapeutic potential in the treatment of inflammatory diseases and certain cancers.
Murphy
G J
GJ
Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, NFSP(N), Coldharbour Road, Harlow, CM19 5AD, Essex, UK. Greg_Murphy-1@sbphrd.com
Holder
J C
JC
D000818:Animals; D004268:DNA-Binding Proteins / Q000819:agonists / Q000737:chemistry / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D008024:Ligands; D009369:Neoplasms / Q000188:drug therapy; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000737:chemistry; D013844:Thiazoles / Q000737:chemistry / Q000627:therapeutic use*; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000819:agonists* / Q000737:chemistry
D004268:DNA-Binding Proteins; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; C089946:2,4-thiazolidinedione